HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Short-term versus longer term pimozide therapy in Tourette’s syndrome: A preliminary study

*See the Appendix for a list of investigators and institutions of the Tourette Syndrome Study Group.

Address correspondence to Dr. Neeru Sehgal, Department of Neurology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 673, Rochester, NY 14642; e-mail: nsehgal{at}mail.neurology.rochester.edu

The authors randomized 10 patients (age range, 7 to 13 years) with Tourette’s syndrome who had achieved a stable level of tic control on open-label pimozide to continue on pimozide (n = 6) or be withdrawn from therapy (n = 4) in a double-blind study. The median time to end point (the time when an increased dose of study medication was required to control tics) was 231 days (continued) versus 37 days (withdrawn), and the survival curves were significantly different (p = 0.02). Chronic, longer term treatment with pimozide appears to be more effective in controlling the course of tics than using the drug acutely to treat an exacerbation.

This article has been cited by other articles:

				E. J. Pappert, C. G. Goetz, E. D. Louis, L. Blasucci, and S. Leurgans Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome Neurology, October 14, 2003; 61(7): 936 - 940. [Abstract] [Full Text] [PDF]